Blog
RSS FeedPosted by Michael Wonder on 21 Jul 2022
Aotearoa less affected by medicine supply issues than other countries
22 July 2022 - PHARMAC’s work behind the scenes and unique arrangements with suppliers means New Zealand has been less ...
Posted by Michael Wonder on 14 Jul 2022
PHARMAC widens access for COVID-19 anti-viral treatments
14 July 2022 - Pharmac has confirmed today that it is further widening access to the three anti-viral treatments it ...
Posted by Michael Wonder on 14 Jun 2022
PHARMAC seeks views on access criteria for COVID-19 treatments
14 June 2022 - PHARMAC is seeking feedback on access criteria for two new COVID-19 treatments – tixagevimab with cilgavimab ...
Posted by Michael Wonder on 24 May 2022
COVID-19 anti-viral access criteria assessment tool
24 May 2022 - PHARMAC has released an online tool to help clinicians identify who’s eligible for funded COVID-19 anti-viral ...
Posted by Michael Wonder on 28 Apr 2022
Access criteria for antiviral treatments widened as molnupiravir arrives in New Zealand
28 April 2022 - PHARMAC is widening access to the antivirals to treat people with early COVID-19, after receiving feedback from ...
Posted by Michael Wonder on 27 Apr 2022
Arthritis patients suffer after medication diverted due to COVID-19
27 April 2022 - Rheumatoid arthritis sufferers have been left in pain as one of their medications was diverted for ...
Posted by Michael Wonder on 31 Mar 2022
PHARMAC secures advance purchase agreement for a pre-exposure COVID-19 treatment
31 March 2022 - PHARMAC has negotiated an agreement with AstraZeneca for its pre-exposure prophylactic COVID-19 treatment, which would be targeted ...
Posted by Michael Wonder on 30 Mar 2022
Pfizer’s oral COVID-19 treatment arrives in New Zealand
31 March 2022 - The first shipment of Pfizer’s new oral antiviral treatment for COVID-19, Paxlovid, has arrived in New ...
Posted by Michael Wonder on 18 Mar 2022
Advocates say PHARMAC too slow on drugs to help treat COVID-19
19 March 2022 - Kiwis have been left waiting for a new antiviral drug to treat COVID-19 because PHARMAC was too ...
Posted by Michael Wonder on 10 Mar 2022
Ronapreve: first COVID-19 therapeutic drug to get Medsafe's approval not effective against Omicron
10 March 2022 - The first new COVID-19 therapeutic drug to get Medsafe's approval demonstrates "significantly diminished potency" against Omicron. ...
Posted by Michael Wonder on 04 Mar 2022
PHARMAC updates access criteria for remdesivir
4 March 2022 - PHARMAC has heard from our expert advisors and clinicians treating people with COVID-19 that we need to ...
Posted by Michael Wonder on 28 Feb 2022
PHARMAC ensures earlier access to key COVID-19 treatment
28 February 2022 - The access criteria for remdesivir is being temporarily widened to allow hospitals to treat those with ...
Posted by Michael Wonder on 16 Feb 2022
PHARMAC publishes experts’ advice and seeks views on access criteria for COVID-19 treatments
16 February 2022 - PHARMAC is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient ...
Posted by Michael Wonder on 31 Jan 2022
New Zealand Pharmaceutical Schedule - 1 February 2022 update
1 February 2022 - The Febuary 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 26 Jan 2022
PHARMAC confirms access criteria for COVID-19 treatments
26 January 2022 - PHARMAC has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with ...